Recent

% | $
Quotes you view appear here for quick access.

Shire plc Message Board

gladpick 18 posts  |  Last Activity: Jun 18, 2015 9:55 AM Member since: Jan 24, 2000
  • Reply to

    CGRP antagonsit and Migraine

    by rojospan Jun 18, 2015 12:06 AM
    gladpick gladpick Jun 18, 2015 9:55 AM Flag

    I think Leiden is a hard working and well intentioned person but I do not think he is capable of working on several major projects at the same time. He is very good in taking up ONE project and complete it and that is the CF project. Unfortunately, that is his personality type -- well intentioned but inappropriate to lead a company like VRTX. He is the type of person who is great as a PROJECT MANAGER, and I guess he has been a good project manager for CF but that is it.

  • Reply to

    Plan to market the placebo instead of Orscambi

    by dumontlaw Jun 16, 2015 5:16 PM
    gladpick gladpick Jun 16, 2015 8:16 PM Flag

    That is a stupid statement and not based on facts shorty.

  • Reply to

    WHY IS VRTX TRADING DO POORLY?

    by cashbar1 Jun 16, 2015 2:41 PM
    gladpick gladpick Jun 16, 2015 4:19 PM Flag

    Let's hope. On the other hand one could say the upside is already baked into the present PPS.

    As i have said many times before,.Leiden's obsession with CF with not much publicity about other non Cf drugs gives investors cold feet. The other issue is that the CF Foundation with its windfall by cashing the VRTX royalties is granting money to other drug companies such as Genzyme and some university scientists to look for better drugs for CF. That as well as other major companies nipping at VRTX CF franchise is making investors uneasy. VRTX investors including myself are asking what is VRTX doing with all of its scientists. It has a bloated payroll. I am hoping Leiden will start realizing that he needs to pay lots of attention to other drugs and move them through the pipeline as fast as possible.

  • "This in vitro observation suggests that the addition of P-1037 to the investigational combination of lumacaftor and ivacaftor could enable enhanced function of the cell’s cilia to clear mucus from the cell surface, potentially resulting in improved lung function."

    If it works it would be a great improvement in the life of CF patients.

  • Reply to

    THE FDA COMMITTEE VOTE THAT COULD SINK VERTEX

    by cashbar1 May 28, 2015 8:07 PM
    gladpick gladpick May 29, 2015 11:08 AM Flag

    In addition to verity and Qdelfan input, let me throw in my 2 cents worth.

    For the sake of argument, let's just say the FDA is not going to approve Orkambi. In that case they have to reiterate the flimsy reason they gave in their presentation to the ADCOM panel which was the improvements were due to Kalydeco and not due to Lumacaftor. Keep in mind it was the FDA that initially did not approve Kalydeco for the 8,500 additional patients who had 2 copies of F508del mutation genes.

    So if they are saying Kalydeco is effective for this new group of patients as well, then logic dictates that they must approve kalydeco alone for these 8,500 additional patients which means VRTX would be able to collect an additional $300,000 for each one of these8,500 patients and does not even need to pay the cost of manufacturing Lumacaftor.

  • gladpick by gladpick May 26, 2015 8:02 PM Flag

    The important thing is the number of scripts filled every week and any uptrends in the numbers. So can any of you smart investigators who post here can find out a source that gives the numbers on a weekly basis? That would be much more helpful than what some of these unknown so called salespeople are saying.

    Of course I realize such data may not exist.

  • gladpick by gladpick May 12, 2015 4:19 PM Flag

    It is very important for SRPT management to line up kid who could testify in the FDA's ADCOM meeting that they need this drug to be approved.

    I will listening to AF who was posting the proceedings of VRTX ADCOM meeting today. The most compelling impressions made on the panel members were those by patients and their families who testified about how VRTX drug combination helped them. Below ist AF advice to SRPT management:

    "SRPT and BMRN take notice: Patient testimony is important!!"
    regarding the effect of patients and their family testimony, AF stated the effect that patients testimony had on the ADCOM committee members:

    "Morrato admits to being swayed by patient testimony, that stuff matters,"

  • Reply to

    absolutely furious with fda

    by verityvoila May 8, 2015 9:17 AM
    gladpick gladpick May 8, 2015 9:57 AM Flag

    I have always maintained that lots of these so called FDA scientists who evaluate drug data do not know what they are doing. Let's face it, they are not the best or they will be working for a drug company making many times as much money as they are on government payroll.

    BTW, please don't tell me they are a dedicated bunch who are forgoing money so they can help humanity!

  • Tiny Corbus looks to take on Vertex with experimental lung drug
    BY Reuters
    — 5:40 PM ET 05/04/2015
    By Natalie Grover
    May 4 (Reuters) - Corbus Pharmaceuticals Holdings Inc's ( CRBP
    Loading...
    Loading...
    ) experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's ( VRTX
    Loading...
    Loading...
    ) successful treatment, Kalydeco.
    Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop the drug, Resunab, and expects to begin a mid-stage study this quarter.
    The company hopes Resunab will treat every patient suffering from the disease, compared with Kalydeco, which has approval to treat a small section of patients. The disease currently affects 70,000 people worldwide.
    Kalydeco treats certain underlying genetic mutations behind cystic fibrosis (CF), while Resunab aims to manage the inflammation the disease causes.
    "We're not focusing on a particular subset of patients, like Vertex's drug," Chief Executive Yuval Cohen said.
    Kalydeco, which was granted fast-track status by the U.S. Food and Drug Administration, received approval in 2012, six years after the company started an early stage trial.
    Kalydeco, which had sales of about $464 million in 2014, is being tested in combination with other drugs to expand its use.
    It is expected to generate peak sales of $1.1 billion in 2020, according to Thomson Reuters Cortellis.
    Resunab could bring in more than $2 billion in U.S. sales treating CF patients, Zacks Investment Research analyst Jason Napodano said.
    Still, Corbus has a long way to go.
    "It's too soon to know how significant Resunab will be ...," said a CF Foundation spokeswoman.
    CF is caused by a missing or defective gene that makes the body produce a thick, sticky mucus resulting in inflammation and bacterial infections.
    This then causes "abnormal inflammation," which leads to fibrosis, and, eventually, death.
    "T

  • Reply to

    VX 765 and epilepsy

    by rojospan May 2, 2015 6:59 PM
    gladpick gladpick May 3, 2015 12:23 PM Flag

    "VRTX pipeline beyond CF remains a conundrum."
    I totally agree and have said it before several times. Leiden seems to be one of those scientists that can only concentrate on one thing at a time. Unless he gets off of his #$%$, or the BOD requires him, and start taking all of these potential compounds through trials I am afraid we will have a fiasco on our hands similar to Telaprevir. All we need is another company coming up with a better drug for cf and we are dead the way Lleiden is leading VRTX.

  • At least one positive news from these idiots at NKTR:

    "The trial compares NKTR-181 to placebo in opioid-naive patients with chronic low back pain with approximately 200 patients being randomized to each arm."

    Of course we all remember the idiotic trial design for 181 which failed. At least the new design makes sense -- compares181 with PLACEBO which should have done originally.

    OMG, I can not believe these incompetents finally have come up with a drug design that makes sense!

  • Reply to

    White elephant in the room

    by ofjames Apr 30, 2015 6:07 PM
    gladpick gladpick Apr 30, 2015 6:35 PM Flag

    "discussion with the FDA by the END OF THE YEAR?"

    Well the answer is very obvious. The longer this painful episode drags on, the longer amount of time the incompetent HR and the idiots around him have to get more free options and sell them pocketing the money while laughing about how they misled us.

    Remember, HR saying "the results of 102 were SO GOOD WE DECIDED TO KEEP IT FOR OURSELVES" rather than partnering it?

    I have been investing for over 40 years and invested in many biotech companies as well as observed the operations of many others for possible investments . In all honesty, I can tell you HR is the worst CEO I have encountered.

    Sometimes, incompetent CEO's at least have a knack in finding competent people to work for them to compensate for their own incompetency. Unfortunately, the incompetent HR does not have that knack and surrounds himself with incompetent people like himself. That is a double whammy for us long term investors!!

    The problem is that he also has recruited some incompetent people for the Board of Directors who keep him in his role instead of firing him.

  • Reply to

    Why

    by corona_and_a_cigar Apr 29, 2015 11:57 AM
    gladpick gladpick Apr 29, 2015 9:15 PM Flag

    "This is not something that Nektar derived on it's own the FDA played a big hand it the how"

    How do you know that? HR has not said a better efficacy was required by the FDA. If in fact that was the case, HR should have told us about it when he announced the trial design that it was the FDA's requirement.
    If in fact the FDA did require better efficacy then let us face it 102 is a failure for the most part.

    Regarding the FDA approving 102 for the 2 indications that showed good efficacy, I am not very optimistic because historically the FDA has not allowed cherry picking of data as some optimists here suggest. Of course I hope I am wrong about that.

    If the FDA did not require a better efficacy and HR and the idiots around him decided they would go beyond the minimum requirement of proving improved side effects then the HR stooges on the board should fire this incompetent CEO. Enough missteps, enough blunders, enough failures. It is abut time to have a competent person hired to get this sinking ship back afloat!

  • Reply to

    concerts pharma deuterated ivacaftor

    by tychoon64 Apr 25, 2015 3:16 AM
    gladpick gladpick Apr 25, 2015 8:40 PM Flag

    NKTR Pharmaceuticals uses a process PEGylation conjugate technology to improve existing drugs. It only does that with drugs that are not patented for the very reason that they know patent owned drug owners will sue the hell out of them once they spend tons of money to prove their product is better than the patented drug and they could lose their #$%$ in suck a litigation that they are bound to lose. these patent violators only hope that if their product is an improved version the patent owners will buy them out. I would not want to own such a company because they first of all may not be successful and even if they are the patent owner will not be willing to pay a lot to buy them out.

    That is why NKTR only works on drugs whose patents have expired.

  • gladpick gladpick Apr 24, 2015 5:13 PM Flag

    Not true. I am here and enjoying PPS near all time high. Good luck to your short. You will need it.

  • Reply to

    Notice Sunnycalifornia..../Kennedy

    by cow_4_beans Apr 20, 2015 4:54 PM
    gladpick gladpick Apr 20, 2015 6:17 PM Flag

    Cow, please send it to my yahoo email. Thanks.

  • gladpick gladpick Apr 20, 2015 12:41 PM Flag

    I Think NKTR will add a point or two from here if the BOD immediately fire HR. The problem with PPS has been, is, and will be as long as this incompetent person is allowed to head NKTR.

  • gladpick gladpick Apr 14, 2015 4:27 PM Flag

    Frankly after 102 did not meet its end points, to be honest, I was so upset with HR that I proceeded with a post that indicated he should now be fired. I decided not to publish it because of all the unrelated #$%$ that Kennedy and his aliases pollute this board with by not giving him more reasons to publish his unintelligent posts.

    In a post, however, I did raise a question that indicated my displeasure with the failure.

    Through my posts for the past 7 years I have repeatedly complained about the incompetency of HR only to be lambasted by Multi while he was alive (may God bless his soul - he always did have good intentions though) as well as a few other long term holders.

    All along HR and his teams had tooted 102 for its low side effects and for its efficacy to be at least as good as Irinotecan. I do not understand why they moved the goal post higher than that only to end up in failure. One always aims at the minimum and if the results end up better, that is gravy. Even though questions have been raised as to why the higher efficacy requirements were included in the study, HR has not responded as far as I know..

    It seems to me if the FDA required higher efficacy for 102 then 102 is dead. If FDA did not require it and the higher efficacy inclusion was HR and his team's idea then they should be fired.

    HR and his incompetent scientific and medical officers, in failing several times including not partnering 102, failing 181 for faulty design, and now with 102 fiasco have caused us a lot of pain.
    Frankly, the only reason I am sticking with this stock is because of the tremendous potential
    in its technology. As far as this management is concerned I believe it is time to give HR his pink slip and hire a competent person to run the show.